NASDAQ: ADMA · Life Sciences · 5 alerts · CIK 1368514
Share price
$13.47Close, Nov 16
Market cap
$2.99B
Shares outstanding
221.85MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Adma Biologics, Inc. filings on SEC EDGAR ↗
ADMA Biologics reported 221,854,389 shares of common stock outstanding as of October 30, 2026, and is classified as a large accelerated filer. The company continues to focus on the commercialization of its primary products, ASCENIV and BIVIGAM, while managing a portfolio that includes Nabi-HB and a network of plasma collection centers.
ADMA Biologics reported third quarter 2026 financial results, highlighted by a 5% year-over-year increase in total revenue to $141.1 million and a 37% increase in GAAP net income to $49.9 million. The growth was primarily driven by ASCENIV revenue, which rose 31% to $124.7 million due to expanding physician adoption and patient starts. The company reiterated its full-year 2026 revenue guidance of at least $530 million while increasing its adjusted earnings outlook.
Term
3 months ended September 30, 2026
“Our third quarter results demonstrate ADMA’s ability to translate accelerating ASCENIV demand into substantial earnings growth. ASCENIV revenue increased 31% year-over-year, driven by expanding physician adoption, new patient starts and growing end-user utilization.”
Adam Grossman, President and Chief Executive Officer
“Our expanding real-world health outcomes evidence strengthens ASCENIV’s clinical value proposition among medically complex primary immunodeficiency patients and supports growing commercial adoption. With our yield-enhanced manufacturing capabilities, robust cash generation and disciplined capital allocation, we believe ADMA is well positioned to deliver sustained, profitable growth and long-term stockholder value creation.”
Adam Grossman, President and Chief Executive Officer